Serum insulin-like growth factor (IGF)-I and IGF-binding proteins in lung cancer patients.
10.3346/jkms.1999.14.4.401
- Author:
Dae Yeol LEE
1
;
Sun Jun KIM
;
Yong Chul LEE
Author Information
1. Department of Pediatrics, Chonbuk National University Medical School, Chonju, Korea.
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Serum;
Insulin-like growth factor-l;
Insulin-like growth factor binding proteins;
Lung neoplasms
- MeSH:
Adenocarcinoma/diagnosis;
Adenocarcinoma/blood;
Adult;
Aged;
Blotting, Western;
Carcinoma, Small Cell/diagnosis;
Carcinoma, Small Cell/blood*;
Carcinoma, Squamous Cell/diagnosis;
Carcinoma, Squamous Cell/blood;
Female;
Human;
Insulin-Like Growth Factor Binding Protein 3/blood*;
Insulin-Like Growth Factor I/metabolism*;
Insulin-Like Growth Factor II/analysis;
Insulin-Like Growth Factor-Binding Protein 2/blood*;
Lung Neoplasms/diagnosis;
Lung Neoplasms/blood*;
Male;
Middle Age;
Radioimmunoassay;
Tumor Markers, Biological
- From:Journal of Korean Medical Science
1999;14(4):401-404
- CountryRepublic of Korea
- Language:English
-
Abstract:
Many studies have shown that insulin-like growth factors (IGF-I & IGF-II) are implicated in the autocrine and paracrine growth of various tumors. Alterations in serum IGFs and IGF-binding proteins (IGFBPs) profiles have been reported in lung cancer. In this study, we measured serum levels of IGF-I and IGFBPs in 41 patients with lung cancer (small cell lung cancer, SCLC, 9; non-small cell lung cancer, NSCLC, 32) by radioimmunoassay and Western ligand blot (WLB). The serum IGF-I level in patients with lung cancer was significantly lower than in controls (207.9+/-62.6 vs 281.3+/-53.9 ng/mL, p<0.01). Patients with NSCLC showed significantly lower serum levels of IGF-I compared with SCLC patients (194.0+/-62.9 vs 258.4+/-27.8 ng/mL, p<0.01). Patients with squamous cell carcinoma tended to show lower serum levels of IGF-I than in those with adenocarcinoma (187.9+/-63.6 vs 215.9+/-59.5 ng/mL, p>0.05). The concentration of IGFBP-3 in lung cancer was 48% of that found in controls by WLB. The serum level of IGFBP-2 was markedly elevated in patients with lung cancer compared with controls (1303.7+/-618.0 vs 696.2+/-300.5, p<0.01). However, there was no significant difference between SCLC and NSCLC groups. This result showed that serum level of IGF-I/IGFBPs may be useful markers for diagnosing and identifying tumor types in lung cancer and further studies are needed.
